Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Thyroid Carcinoma, Version 2.2014 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D., Dickson, P., Duh, Q., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., Lydiatt, W. M., McCaffrey, J., Moley, J. F., Parks, L., Raeburn, C. D., Ridge, J. A., Ringel, M. D., Scheri, R. P., Shah, J. P., Sherman, S. I., Sturgeon, C., Waguespack, S. G., Wang, T. N., Wirth, L. J., Hoffmann, K. G., Hughes, M. 2014; 12 (12): 1671-1680

Abstract

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

View details for Web of Science ID 000346190900005